Aromatization: How Testosterone Becomes Estradiol and Why It Matters

Aromatization often enters the conversation in hormone medicine after an estradiol result comes back higher than expected, particularly in a man receiving testosterone therapy. Testosterone rises with treatment, estradiol rises as well, and attention quickly shifts to whether that conversion should be reduced.

There are situations in which a higher estradiol result deserves further evaluation, but aromatization itself is not an abnormal side effect of testosterone. It is a normal metabolic pathway. The aromatase enzyme converts a portion of testosterone into estradiol, supplying much of the estradiol found in men. Aromatase also contributes to estrogen production in women and becomes increasingly relevant in peripheral tissues after ovarian estrogen production declines.

Clinical interpretation depends on more than the estradiol number. Testosterone exposure, symptoms, body composition, SHBG, medications, metabolic health, liver function, and the reliability of the laboratory assay can all influence how the result should be understood.

For the broader clinical framework, see the Hormone Optimization and Longevity Medicine Hub.

What Is Aromatization?

Aromatase is an enzyme encoded by the CYP19A1 gene. It converts androgens into estrogens. Testosterone can be converted into estradiol, while androstenedione can be converted into estrone.

Aromatase is expressed in adipose tissue, bone, brain, reproductive tissues, and several other sites. This distribution is clinically relevant because sex hormones are not simply produced by one gland, released into the circulation, and delivered unchanged to every tissue. Hormones can also be converted locally, creating a tissue-level hormone environment that may not be fully represented by a serum measurement.

Testosterone illustrates this well. Some of its effects are mediated directly through the androgen receptor. Others involve conversion to dihydrotestosterone, while some depend in part on aromatization to estradiol and subsequent estrogen-receptor signaling. Testosterone physiology therefore includes both direct androgen effects and the effects of its downstream metabolites.

Aromatization in Men

Estradiol is sometimes treated in men's hormone discussions as though it were an unwanted byproduct of testosterone. Male physiology is more complicated. Only part of a man's estradiol is produced directly in the testes. A substantial portion of circulating estradiol comes from peripheral aromatization of testosterone and other androgen precursors.

The biological importance of this pathway became particularly clear in rare men with aromatase deficiency or impaired estrogen signaling. Despite adequate androgen exposure, these men developed abnormalities in skeletal maturation, including low bone mass and failure of normal growth-plate closure. Restoration of estrogen signaling could improve skeletal development.

Experimental research in otherwise healthy men has reached a similar conclusion. When estradiol is markedly suppressed, bone resorption increases. Estradiol therefore plays a meaningful role in the male skeleton alongside testosterone.

Estradiol also participates in reproductive hormone signaling and sexual physiology. The relative contribution of testosterone and estradiol varies by tissue and function, which is why an approach focused simply on maximizing testosterone while minimizing estrogen does not reflect normal male endocrine physiology.

Aromatization in Women

During the reproductive years, the ovaries are the dominant source of estradiol in women, although aromatization outside the ovaries continues to contribute to estrogen physiology. The balance changes after menopause as ovarian estradiol production falls.

Peripheral tissues continue converting androgen precursors into estrogens after menopause, and adipose tissue is one of the important sites where this occurs. Estrone becomes a more prominent circulating estrogen, while estradiol concentrations are substantially lower than they were during the reproductive years.

Peripheral estrogen production helps explain why estrogen physiology does not disappear after menopause. Body composition, adrenal androgen production, medications, liver metabolism, and other factors can continue to influence the postmenopausal estrogen environment even after ovarian hormone production changes dramatically.

Body Fat, Aromatase, and the Obesity Question

Adipose tissue expresses aromatase, and greater adipose mass can contribute to increased peripheral conversion of androgens into estrogens. That biology is well established. Problems arise when aromatization is used as a complete explanation for obesity-related low testosterone.

Men with obesity can have lower total testosterone for several reasons. Insulin resistance and hyperinsulinemia can reduce SHBG, which in turn lowers measured total testosterone. Inflammatory signaling, leptin resistance, hypothalamic and pituitary changes, sleep disruption, sleep apnea, liver metabolism, medications, and direct effects on testicular function may also contribute.

Low SHBG deserves particular attention because a low total testosterone concentration in a man with obesity or insulin resistance does not necessarily describe free testosterone accurately. The total and free testosterone results may tell different stories depending on SHBG concentration and the method used to estimate or measure free testosterone.

Body fat can therefore influence aromatization without making excessive estrogen conversion the sole cause of low testosterone. Evaluation is more useful when aromatase is considered as one part of a broader metabolic and endocrine picture.

What Happens to Estradiol During Testosterone Therapy?

Testosterone therapy increases the amount of testosterone available to tissues, including the testosterone available for aromatization. Estradiol commonly rises as testosterone rises, and an increase by itself does not establish that treatment is inappropriate.

Consider a man who begins treatment with low testosterone and symptoms consistent with androgen deficiency. Testosterone therapy brings his testosterone into an appropriate physiologic range, his symptoms improve, and estradiol increases at the same time. If he has no breast symptoms, unexpected fluid retention, or other clinical concerns, the higher estradiol value may simply reflect the increase in testosterone exposure.

The picture is different when testosterone exposure is excessive or when laboratory changes accompany new symptoms or treatment complications. Supraphysiologic testosterone concentrations, breast tenderness, edema, significant erythrocytosis, acne, or other changes should prompt a review of the overall regimen. Testosterone dose, formulation, injection interval, timing of laboratory testing, and individual pharmacokinetics may all contribute.

Reducing estradiol without first reviewing testosterone exposure can lower a laboratory value while leaving the reason for the elevation unchanged.

For more on testosterone treatment, see Testosterone Therapy for Men Over 40.

Aromatization and Bone Health

Bone health is one of the clearest reasons to be cautious about unnecessary estradiol suppression. Estradiol helps regulate bone remodeling in both women and men, and a meaningful portion of estrogen exposure in men comes from the aromatization of testosterone.

Very low estradiol concentrations in men can increase bone turnover and contribute to loss of bone mineral density. Aromatase deficiency provides a more extreme example of the same physiology, with profound effects on skeletal maturation and bone mass.

Testosterone also has direct skeletal effects, particularly through its influence on cortical bone, muscle, and mechanical loading. Testosterone and estradiol therefore contribute to bone health through overlapping pathways rather than functioning as competing hormones.

This becomes clinically relevant when long-term aromatase inhibition is being considered. Lowering estradiol may change the laboratory result being targeted while increasing skeletal risk if suppression becomes excessive.

When bone health is a concern, direct assessment is more useful than trying to infer skeletal status from estradiol alone. DEXA bone density and body composition testing provides objective information about bone mineral density while also allowing assessment of body composition that may be relevant to hormone and metabolic health.

When Higher Estradiol Deserves Attention

A rise in estradiol during testosterone therapy can be physiologic, but higher values should not automatically be dismissed. Markedly elevated results, new breast tenderness or enlargement, unexpected changes in sexual function, unexplained fluid retention, liver disease, medication effects, excessive testosterone exposure, or other endocrine abnormalities may justify further evaluation.

Gynecomastia illustrates why the laboratory value needs clinical context. Breast tissue responds to the balance between estrogen and androgen signaling rather than to a single estradiol concentration. Age, medications, liver disease, obesity, gonadal disease, testosterone exposure, and other factors may contribute.

An unexpectedly high estradiol result in someone who is not receiving testosterone also warrants attention. Repeating a questionable measurement with an appropriate assay and evaluating potential causes is usually more informative than assuming that increased aromatase activity is responsible.

Where Aromatase Inhibitors Fit

Aromatase inhibitors reduce the conversion of androgens into estrogens. They have established medical uses, particularly in the treatment of estrogen-sensitive breast cancer, and selected applications in male reproductive and endocrine medicine. Many of the latter uses are off-label and are supported by a more limited evidence base than their use in oncology.

Routine aromatase inhibition is not necessary for every man receiving testosterone therapy. Excessive suppression of estradiol can affect bone health and may contribute to sexual or other symptoms.

When estradiol is elevated during testosterone treatment, evaluation can include testosterone dose and delivery, timing of injections or other administration, the timing of laboratory testing, body composition, SHBG, medications, alcohol intake, liver health, symptoms, and the reliability of the estradiol assay. Reviewing those factors can clarify whether estradiol reflects excessive testosterone exposure, altered metabolism, assay limitations, or expected physiology.

Some patients may ultimately have a reasonable indication for an aromatase inhibitor. That decision is different from automatically adding estrogen suppression whenever estradiol rises during testosterone therapy.

What About the Testosterone-to-Estradiol Ratio?

The testosterone-to-estradiol ratio is discussed frequently in men's hormone care, particularly in relation to obesity, fertility, and testosterone treatment. It can be informative in selected clinical settings, but there is no universally validated ratio that men need to achieve for longevity, sexual function, body composition, or cardiovascular health.

Interpretation depends on the absolute testosterone and estradiol concentrations, symptoms, SHBG, fertility goals, treatment status, body composition, and laboratory methodology. A calculated ratio may provide additional context, but it should not replace interpretation of the individual hormone measurements or the clinical picture.

Testing Estradiol in Men Requires the Right Assay

Estradiol concentrations in men are substantially lower than those commonly seen in premenopausal women. Some routine immunoassays perform less reliably at these lower concentrations, which can become clinically significant when treatment decisions are being made from relatively small differences in the result.

When accurate estradiol measurement is important in a man, a sensitive method such as liquid chromatography-tandem mass spectrometry may provide greater reliability, particularly at lower concentrations.

Estradiol should then be interpreted alongside the remainder of the hormone panel. Total testosterone, free testosterone, SHBG, and, when appropriate, LH and FSH can provide additional information depending on whether the patient is untreated, receiving testosterone therapy, or being evaluated for another endocrine concern.

Metabolic and body-composition data may be equally important. Fasting insulin, glucose, A1c, liver health, visceral fat, and sleep apnea risk can help explain a low-testosterone pattern that might otherwise be attributed too quickly to estradiol.

For more on these parts of the hormone panel, see SHBG and Longevity and Free vs. Total Testosterone.

Aromatization in Longevity Medicine

Aromatization belongs in longevity medicine because testosterone and estradiol influence bone, body composition, reproductive physiology, sexual health, and other systems that change with age. The enzyme itself, however, is not a longevity target that needs to be minimized or optimized in isolation.

A healthy hormone strategy is not defined by achieving the lowest possible estradiol concentration. Men with obesity and low testosterone do not automatically need estrogen suppression, and men receiving testosterone do not necessarily require treatment when estradiol increases. The testosterone-to-estradiol ratio also has no established role as a general marker of healthspan.

The more useful clinical approach is to identify the physiology behind the hormone pattern. Testosterone dose may be excessive. Visceral fat and insulin resistance may be contributing. SHBG may be low. Medication use, liver disease, thyroid disease, sleep apnea, or another endocrine condition may be relevant. In other cases, the estradiol result may be entirely consistent with the testosterone concentration and the patient's clinical status.

Aromatization is normal physiology. Treatment decisions are best made by understanding when the pathway is functioning as expected and when the broader hormone pattern deserves further evaluation.

Related Longevity Medicine Resources

FAQ: Aromatization, Testosterone, and Estradiol

What is aromatization?

Aromatization is the enzymatic conversion of androgens into estrogens. The aromatase enzyme converts testosterone into estradiol and androstenedione into estrone.

Is aromatization bad?

No. Aromatization is a normal part of human hormone physiology and provides much of the estradiol found in men. Whether a particular estradiol result needs attention depends on testosterone exposure, symptoms, body composition, SHBG, medications, metabolic health, and other clinical factors.

Does body fat increase aromatization?

Adipose tissue expresses aromatase and can contribute to peripheral estrogen production. Obesity-related hormone changes also involve SHBG, insulin resistance, inflammatory signaling, sleep, liver metabolism, hypothalamic-pituitary function, and other factors.

Why do men need estradiol?

Estradiol contributes to male bone health as well as reproductive, sexual, metabolic, and neuroendocrine physiology. Much of the estradiol found in men is produced from testosterone through aromatization.

Does testosterone therapy raise estradiol?

It often does. Increasing testosterone provides more substrate for aromatase, so estradiol may rise during treatment. The increase does not by itself establish that treatment is inappropriate or that estradiol should be suppressed.

Should every man taking testosterone also take an aromatase inhibitor?

No. Aromatase inhibitors are not routinely required simply because testosterone treatment increases estradiol. Excessive estradiol suppression can adversely affect bone and may contribute to other symptoms.

Does high estradiol always mean too much aromatization?

No. Testosterone dose, body composition, medications, liver function, laboratory methodology, and other endocrine conditions can influence estradiol. The reason for an unexpected result should be evaluated before treatment is considered.

Is there an ideal testosterone-to-estradiol ratio?

No universally accepted testosterone-to-estradiol ratio has been established as an optimal target for health or longevity. Absolute hormone concentrations, symptoms, SHBG, treatment status, fertility goals, and clinical context are more useful than trying to achieve a single ratio.

What estradiol test is best for men?

Because estradiol concentrations are relatively low in men, sensitive laboratory methods are preferable when precise measurement is clinically important. Liquid chromatography-tandem mass spectrometry is commonly used when greater accuracy at lower concentrations is needed.